Posts Tagged ‘MASH’

Survodutide and Tirzepatide Dash for a Splash with MASH

June 9, 2024 — At the EASL Congress 2024 in Milan, we witnessed quite a splash of new data on both survodutide and tirzepatide for MASH. Friday and Saturday gave us two headline presentations at the meeting and two publications in the New England Journal of Medicine. Lilly pronounced itself “very pleased” with the results of their SYNERGY-NASH study […]

A Little More Detail on Tirzepatide in MASH at EASL

June 6, 2024 — On the opening day of the EASL Congress in Milan, we got a peek at more details on the results of the phase 2 study of tirzepatide in MASH (metabolic dysfunction associated steatohepatitis). The study, called SYNERGY-NASH, will be the subject of a late-breaking presentation on Saturday at the meeting. But the release of the […]

Five Things to Seek at ECO 2024

May 9, 2024 — We’re packing our bags for Venice, where the European Congress on Obesity (ECO 2024) will start in just a few days. A lot will be coming at us in a short space of time, so taking time to set some priorities is essential. Thus, we have a short list of things that we’ll be seeking […]

Low-Dose Aspirin in MASLD: Preliminary Data on a Thrifty Option

March 21, 2024 — For an early stage of hepatic steatosis called MASLD, JAMA has just published results from an intriguing study. It is a small RCT showing that low-dose aspirin can significantly reduce fat in the liver of persons with MASLD and without cirrhosis. MASLD is a new acronym for metabolic dysfunction-associated steatotic liver disease. You might know […]

FDA Approves Resmetirom: First Ever for MASH with Fibrosis

March 16, 2024 — Firsts are worth celebrating. In this case, the cause for celebration is especially great. MASH or metabolic steatohepatitis is a disease that is growing dramatically more common and more harmful to the health of the population. Late this week, FDA approved resmetirom to be the first ever treatment for MASH with fibrosis. Note that the […]

Progress Reported in MASH with Survodutide

February 27, 2024 — Yet another GLP-1 agonist in development for obesity – survodutide – showed promising results yesterday from a phase 2 clinical trial in MASH. In case you missed the notice, MASH is the new acronym for what we used to label as NASH. We also note that MASLD has replaced NAFLD in the nomenclature alphabet soup […]

More News Points to Explosive Growth for GLP-1 Medicines

February 7, 2024 — Let’s be clear from the start. Hype about “weight loss” drugs is exquisitely unhelpful. This is because weight loss is only an acute effect of new medicines that act on GLP-1 receptors and related pathways that influence obesity. The real need for these medicines is to control a whole range of chronic health problems that […]

Is This Liver Fatty or Steatotic? Does It Matter?

December 4, 2023 — By the end of this month, we will be seeing lists of what’s in and what’s out for the coming year. For people whose minds drift toward liver disease, we have an entry. Fatty liver is out and steatotic liver is in. NAFLD goes to the dustbin, replaced by MASLD, while MASH takes over from […]